US Pre-Market SEC Filings Roundup — March 13, 2026

13-03-2026

Republic Bancorp, Inc. (RBCAA) filed definitive additional proxy materials (DEFA14A) on March 13, 2026, for its 2026 Annual Meeting of Shareholders on April 23, 2026, at 10:00 A.M. EDT in Louisville, Kentucky. The agenda includes the election of 13 director nominees and ratification of Forvis Mazars as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Shareholders must access materials online at www.investorvote.com/RBCAA or request paper copies by April 13, 2026, to vote.

• ·Proxy materials request deadline: April 13, 2026
• ·Meeting location: Republic Bank Building, Lower Level, 9600 Brownsboro Road, Louisville, Kentucky 40241
• ·Contact: Republic Corporate Center, 601 West Market Street, Louisville, Kentucky 40202; Phone: (502) 560-8628

13-03-2026

Scilex Holding Company announced on March 13, 2026, that it filed a complaint dated March 11, 2026, in the United States District Court for the Central District of California against Marc Wade, The St. James Bank & Trust Company Ltd., Omega & Corinth Group Ltd., certain affiliates (collectively, the 'Wade Defendants'), and Bank of New York Mellon Corporation (BNY). The complaint asserts claims of federal securities fraud (all defendants), state securities fraud (Wade Defendants), fraudulent inducement (Wade Defendants), unlawful conversion (all defendants), and negligence (BNY). This disclosure is furnished under Item 7.01 and not deemed 'filed' for liability purposes.

• ·Complaint filed in the United States District Court for the Central District of California.
• ·Exhibit 99.1: Complaint Filed, dated March 11, 2026.

13-03-2026

Amplify Energy Corp. dismissed Deloitte & Touche LLP as its independent registered public accounting firm effective upon issuance of their Final Audit Reports on March 9, 2026, for the fiscal year ended December 31, 2025; while the financial statement audits for 2025 and 2024 were unqualified, Deloitte issued an adverse opinion on internal control over financial reporting due to a material weakness in controls related to personnel changes lacking technical accounting expertise. The Audit Committee appointed Grant Thornton LLP as the new auditor for fiscal 2026, effective March 11, 2026, with no prior disagreements, reportable events, or problematic consultations. Deloitte confirmed agreement with these disclosures in a letter dated March 13, 2026.

• ·Deloitte authorized to respond fully to Grant Thornton inquiries, including on the Material Weakness.
• ·No disagreements on accounting principles, financial disclosures, auditing scope, or other reportable events during fiscal years 2025, 2024, and interim periods through March 9, 2026.
• ·No consultations with Grant Thornton during fiscal years 2025, 2024, and interim periods through March 11, 2026, regarding accounting principles, audit opinions, disagreements, or reportable events.

13-03-2026

LENSAR, Inc. entered into a Priority Credit Line Agreement (PCL Agreement) with Wells Fargo Bank, N.A. on March 11, 2026, providing a revolving credit facility of up to $9.2 million secured by a first-priority lien on a designated brokerage account. This Form 8-K/A, filed March 13, 2026, amends the original March 12, 2026 filing to clarify the terms, including interest options at fixed (Treasury Yield plus margin) or variable (SOFR plus margin) rates, with customary events of default.

• ·PCL Agreement is a non-purpose margin credit facility.
• ·Events of default include payment failures, bankruptcy, or insufficient collateral value.

13-03-2026

Tonix Pharmaceuticals reported full year 2025 net product revenue of $13.1 million, a 30% YoY increase from $10.1 million, including $1.4 million from the TONMYA launch on November 17, 2025, and growth in legacy products Zembrace, SymTouch, and Tosymra to $11.7 million (up 16% YoY). However, selling, general, and administrative expenses more than doubled to $87.7 million from $40.1 million due to commercialization and headcount increases, while net cash used in operations rose 64% to $99.8 million, resulting in a net loss of $124.0 million (improved from $130.0 million YoY). Cash and equivalents stood at $207.6 million as of December 31, 2025, up significantly from $98.8 million, supported by a $20.0 million registered direct offering.

• ·Cash resources expected to meet planned requirements into Q1 2027.
• ·FDA approved TONMYA in August 2025 based on two Phase 3 trials.
• ·Plans to initiate U.S. field study for TNX-4800 in 2027 pending FDA clearance.
• ·IND cleared for HORIZON Phase 2 study of TNX-102 SL in MDD, enrollment mid-2026.
• ·Phase 2 trial for TNX-1500 in kidney transplant mid-2026 pending FDA clearance.
• ·Phase 2 trial for TNX-2900 in Prader-Willi syndrome Q1 2027.

13-03-2026

Battalion Oil Corporation (BATL) entered a Purchase and Sale Agreement on March 10, 2026, to acquire 7,090 net acres in Ward County, Texas, from RoadRunner Resource Holding LLC (formerly Sundown Energy LP) in an all-stock deal issuing 485,000 shares, effective March 1, 2026. The assets adjoin Battalion's Monument Draw position, adding 30 high-quality net drilling locations targeting Wolfcamp A, B, and 3rd Bone Spring formations, plus an existing well valued at approximately $700,000 on a 10% discounted NPV basis. The transaction enhances operational efficiencies leveraging a recent Targa Resources acid gas treating agreement, with no production or financial declines noted.

• ·Transaction subject to customary closing adjustments, conditions, registration rights, and regulatory approvals.
• ·Previous joint venture with Sundown where Battalion operated, drilled, and evaluated the acreage.

13-03-2026

Bitwise Avalanche ETF filed Amendment No. 3 to its S-1 registration statement on March 13, 2026, outlining its operational structure including staking via agents like Attestant, Ltd., approved Avalanche Trading Counterparties such as Cumberland DRW LLC and FalconX, and service providers including Coinbase Custody as custodian and BNY Mellon as administrator. The Trust will charge a unitary Sponsor Fee of 0.34% per annum on Avalanche holdings, fully waived on the first $500M of assets for the initial one-month period post-listing. No financial performance data or period comparisons are provided in the filing.

• ·Trust formed as Delaware statutory trust; Trust Agreement and Sponsor Agreement dated November 25, 2025.
• ·Sponsor formed June 4, 2018; Avalanche Custodian chartered in 2018.
• ·Pricing Benchmark calculated at 4:00 p.m. ET using data from Bitstamp, Coinbase, Crypto.com, and Kraken.
• ·Indicative Trust Value (ITV) disseminated every 15 seconds during 9:30 a.m. to 4:00 p.m. ET trading hours.

13-03-2026

Ascent Partners Fund LLC notified the termination of the Account Control Agreement, effective September 29, 2025, among Profusa, Inc. (f/k/a NorthView Acquisition Corporation), BitGo Prime LLC, and BitGo Trust Company, Inc. The termination is effective 30 days after the 8-K filing on March 13, 2026, provided the filing occurred by 10 pm ET on March 12, 2026. No financial terms, impacts, or performance metrics are disclosed.

• ·Termination pursuant to Section 9(c) (Termination; Survival) of the Control Agreement
• ·Notice delivered via email on March 12, 2026

13-03-2026

Eupraxia Pharmaceuticals Inc. (EPRX) filed its Form 40-F Annual Report for the fiscal year ended December 31, 2025, incorporating the Annual Information Form, audited consolidated financial statements for 2025 and 2024, and Management's Discussion and Analysis. As of December 31, 2025, the company reported 51,939,206 common shares and 8,355,638 preferred shares outstanding. No specific financial performance metrics such as revenue or net income were detailed in the filing cover; refer to exhibits for full details.

• ·Auditor: KPMG LLP (Vancouver, Canada, Firm ID: 85)
• ·Principal executive offices: 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4
• ·Emerging growth company status confirmed
• ·Filing signed March 12, 2026

13-03-2026

Indivior Pharmaceuticals, Inc. (INDV) announced on March 12, 2026, the pricing of its offering of 0.625% convertible senior notes due 2031. A press release providing further details is filed as Exhibit 99.1 to this Form 8-K. No additional financial metrics, period-over-period comparisons, or performance data were disclosed in the filing.

• ·Notes registered under Section 12(b) of the Act: Common stock, $0.001 par value per share (INDV).
• ·Registrant incorporated in Delaware (Commission File Number 001-37835, IRS EIN 41-2520873).
• ·Principal executive offices: 10710 Midlothian Turnpike, Suite 125, North Chesterfield, VA 23235.

13-03-2026

Picard Medical, Inc. issued a press release on March 12, 2026, announcing a webcasted Annual Business Update on March 25, 2026, at 4:30 p.m. Eastern Time, which will cover fiscal year and Q4 2025 financial results, operational progress, commercial activity, and strategic priorities. The event will feature perspectives from leading clinicians and a patient testimonial regarding the SynCardia Total Artificial Heart, with registration available via the company's website.

• ·Principal executive offices: 1992 E Silverlake, Tucson, AZ 85713; Telephone: (520) 545-1234
• ·Common Stock (par value $0.0001 per share) trades as PMI on NYSE American
• ·Company is an emerging growth company

13-03-2026

Demming Financial Services Corp /ADV filed a 13F-HR on March 13, 2026, disclosing $133.0M in equity holdings across 35 positions as of December 31, 2025. The portfolio is dominated by Dimensional ETF Trust funds, with the largest holding in US Core Equity 2 at $48.2M (1,216,820 shares) and World ex US Core at $41.4M (1,265,222 shares). Other positions include individual stocks like Keycorp ($971,450, 47,066 shares) and Middlefield Banc Corp ($792,799, 22,953 shares), with no prior period data available for comparison.

• ·Filing covers period ending December 31, 2025
• ·All holdings reported with sole voting power (SH SOLE)
• ·Smaller positions include NVIDIA (1,139 shares, $212,431), Tesla (645 shares, $290,069), and Microsoft (753 shares, $364,204)

13-03-2026

13-03-2026

Quest Resource Holding Corp (QRHC) reported FY2025 revenue of $250.2M, down 13.2% YoY from $288.5M, with gross profit declining 14.9% to $42.5M and net loss slightly widening to $15.4M from $15.1M amid ongoing operating losses. While total operating expenses fell 10.6% to $48.7M due to lower depreciation, amortization, and impairment charges, Adjusted EBITDA decreased 35.7% to $9.3M from $14.5M. Positively, net cash from operating activities swung to $9.6M from a $6.1M outflow, total assets shrank to $145.6M with reduced liabilities and debt to $106.0M.

• ·Cash and cash equivalents increased to $1.0M from $0.4M YoY.
• ·Accounts receivable decreased to $49.0M from $62.3M YoY.
• ·Stockholders’ equity declined to $40.5M from $54.2M YoY.
• ·Allowance for doubtful accounts $0.8M as of Dec 31, 2025 (vs $0.8M prior).

13-03-2026

13-03-2026

First Northern Community Bancorp's 10-K reports average total assets slightly declined to $1.89B in 2025 from $1.89B in 2024, while average loans remained nearly flat at $1.05B with yields improving to 5.53% from 5.30%. Net interest income rose 4.8% to $67.5M with margin expanding to 3.77% from 3.60%; however, demand deposits fell 7.3% to $650M and time certificates declined 7.7% to $141M. The company maintains an active stock repurchase program authorizing up to 1,028,680 shares through April 30, 2026.

• ·Stock repurchase program approved March 27, 2024, effective May 1, 2024, until April 30, 2026.
• ·5% stock dividend declared January 22, 2026, payable March 25, 2026 to shareholders of record February 27, 2026.

13-03-2026

13-03-2026

Olenox Industries Inc. (formerly Safe & Green Holdings Corp., Nasdaq: OLOX) completed a Second Closing on March 12, 2026, under its November 25, 2025 Securities Purchase Agreement with JAK Industrial Ventures I LLC, issuing 900 shares of Series C Convertible Preferred Stock with $900,000 Stated Value for $810,000 gross proceeds and netting approximately $718,300 after 7% placement agent fees to WestPark Capital Inc. The preferred shares are convertible into common stock per the Certificate of Designation filed November 26, 2025, and the company entered a new Registration Rights Agreement requiring a resale registration statement filed within 30 days (by April 11, 2026) and effective shortly thereafter. The sale relied on exemptions under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.

• ·Registration statement filing deadline: no later than 30 days from March 12, 2026 (April 11, 2026)
• ·SEC effectiveness deadlines: 30 days after filing (extendable to 45/60 days for partial/full review)
• ·Initial closing disclosed in 8-K filed December 2, 2025
• ·Sale exempted under Section 4(a)(2) of Securities Act and Rule 506(b) of Regulation D

13-03-2026

13-03-2026

Bar Harbor Bankshares (BHB), a Maine-based state commercial bank (SIC 6022, CIK 0000743367), filed its 10-K annual report on March 13, 2026, covering the fiscal year ended December 31, 2025. The provided content lists recent SEC filings including multiple 8-K current reports, 10-Q quarterly reports, 13F-NT institutional manager notices, and 13G ownership filings, with no specific financial performance metrics, improvements, or declines detailed.

• ·Business Address: 82 MAIN ST PO BOX 400 BAR HARBOR ME 04609-0400
• ·Phone: 2076696784
• ·State of Incorporation: ME
• ·Fiscal Year End: December 31

13-03-2026

News Corporation disclosed in its 8-K filing information provided to the Australian Securities Exchange (ASX) regarding its ongoing $1 billion stock repurchase program for Class A (NWSA) and Class B (NWS) common stock. The disclosures, dated as noted in Exhibits 99.1 and 99.2, include forward-looking statements about potential repurchases subject to market conditions. No specific repurchase transactions or amounts were detailed in the filing itself.

13-03-2026

13-03-2026

American Clean Resources Group, Inc. (ACRG) entered into a non-material Master Services Agreement (MSA) with Sustainable Metal Solutions, LLC (SMS) on March 11, 2026, to provide administrative and advisory services without any operational control or economic interest in SMS. This disclosure accompanies previously announced plans to acquire an 80.1% interest in SMS. Separately, SMS's mine permit application faces a procedural administrative hearing before the Colorado Mined Land Reclamation Board on March 18, 2026, regarding a scope reduction classified as an Amendment, with no enforcement action involved.

• ·ACRG common stock: $0.001 par value, trades on OTCPK under ACRG.
• ·Hearing relates solely to administrative classification of DMO permit scope reduction under Colorado Rule 1.1(7).
• ·SMS retains full responsibility for operational, regulatory, and compliance matters.

13-03-2026

13-03-2026

Jefferson Capital, Inc. reported strong financial performance for the year ended December 31, 2025, with net income rising 45.8% to $188.0 million from $128.9 million in 2024, driven by total revenues increasing 41.6% to $613.3 million, primarily from portfolio income growth of 41.4% to $560.4 million. However, interest expense increased 37.1% to $105.8 million from $77.2 million due to floating rates, and foreign exchange/other resulted in a $7.7 million loss versus a $5.5 million gain prior year, while credit card revenue declined 13.3% to $7.2 million. Adjusted net income grew 31.9% to $202.7 million amid higher operating expenses.

• ·Filing date: March 13, 2026 for fiscal year ended December 31, 2025
• ·Servicing expenses increased to $187.2M (30.5% of revenues) from $130.9M (30.2%)
• ·Provision for credit losses decreased to $2.4M from $3.5M
• ·Risks include exposure to CAN-SPAM Act, TCPA, Telemarketing Sales Rule, and Canada's Bankruptcy and Insolvency Act (BIA)
• ·Potential risks from lenders' stringent credit policies reducing debt purchase flow

13-03-2026

13-03-2026

Global Medical REIT Inc. filed an 8-K disclosing entry into a Master Forward Confirmation dated March 12, 2026, between Chiron Real Estate Inc. (Ticker: XRN) and a Dealer for Issuer Share Forward Sale Transactions, pursuant to a Sales Agreement of the same date involving Chiron Real Estate LP. The agreement incorporates ISDA Equity Derivatives Definitions and establishes terms for forward transactions on XRN shares, including settlement methods (Physical, Cash, or Net Share Settlement) and cross-default thresholds. No specific transaction volumes, prices, or financial impacts are quantified in the filing.

• ·Shares have par value $0.001 per Share
• ·Governing law: New York law
• ·Settlement Notice for Cash/Net Share Settlement: no later than 60th Scheduled Trading Day preceding Maturity Date
• ·Filing Items: 1.01, 5.03, 8.01, 9.01

13-03-2026

13-03-2026

CCEP's 2025 annual results showed reported revenue of €20.9B and operating profit of €2.8B, with comparable and FX-neutral figures slightly higher at €21.3B and €2.9B respectively, alongside ROIC of 10.9% reported and 11.5% comparable. Sustainability achievements included an 18.9% absolute reduction in GHG emissions vs 2019, 75.7% of primary packaging collected for recycling, and 105.2% water replenished relative to sales volume. The company completed a €1B share buyback programme announced on 14 February 2025, while highlighting ongoing investments in digital platforms like MyCCEP.com which generated €2.38B in revenue.

• ·Leverage target range: 2.5–3.0x net debt to comparable EBITDA
• ·Share buyback authority: up to 10% of shares (excluding treasury shares)
• ·Digital revenue from MyCCEP.com: €2.38B in 2025

13-03-2026

Cayson Acquisition Corp issued a proxy statement supplement dated March 13, 2026, increasing the monthly Insider contribution from $100,000 to $125,000 (+25%) to fund monthly extensions of its initial business combination deadline from March 23, 2026, up to March 23, 2027, ahead of its extraordinary general meeting on March 18, 2026. The Trust Account held approximately $64.8M as of February 23, 2026 (~$10.80 per share redemption price), with 7,830,000 ordinary shares outstanding as of the February 18, 2026 record date; however, high redemptions could reduce liquidity and per-share contributions (e.g., ~$0.02-$0.04 per share depending on redemptions). Shareholders can redeem shares by March 16, 2026, potentially exceeding open-market values but with liquidity risks.

• ·Redemption deadline: 5:00 p.m. ET on March 16, 2026 (two business days before Meeting).
• ·Meeting details: 10:00 a.m. ET on March 18, 2026, virtually at https://www.virtualshareholdermeeting.com/CAPN2026SM.
• ·Original business combination deadline: March 23, 2026; maximum Extended Date: March 23, 2027 (up to 12 monthly extensions).

13-03-2026

Forum Markets, Incorporated (Nasdaq: FRMM) announced a $10 million revolving warehouse facility agreement for financing fully secured first-lien auto loans originated via Automatic USA and analyzed by Karus, Inc., expecting 12%-13% annualized yield independent of token issuance timing. The 12-month facility enables 24/7/365 loan settlement using blockchain infrastructure from Liquidity.io, collateralized by Texas Capital Bank Government Money Market ETF, to support Forum's strategy of tokenizing real-world credit assets. While generating immediate double-digit yields from warehouse lending, long-term held auto loans are projected at high single-digit yields, blending for enhanced tokenized product returns amid forward-looking risks.

• ·12-month facility term with 7-10 business day loan holding periods
• ·Partners with Automatic USA for automated dealer-level loan applications and Karus for AI-driven credit analytics
• ·Settlement via Liquidity.io blockchain infrastructure for 24/7/365 basis

13-03-2026

Pearson PLC's 2025 annual results showed headline sales up 1% to £3,577m from £3,552m in 2024, with underlying sales growth of 4%, while reported operating profit fell £34m to £507m due to FX headwinds, inflation, and an £87m impairment. Adjusted operating profit increased 2% to £614m, boosted by Virtual Learning (+23% headline adj OP) and Enterprise Learning & Skills (+45%), but offset by declines in Higher Education sales (-1%) and English Language Learning sales (-4%), flat adj OP there (0%), and a 2% drop in Assessment & Qualifications adj OP. Free cash flow rose to £527m from £490m, though net debt widened to £1,069m from £853m.

• ·2026 outlook: underlying sales growth mid-single digit; adjusted operating profit £640m-£685m at FX £:$1.35; free cash flow conversion 90-100%.
• ·Adjusted net finance costs c.£80m due to £350m share buyback funding.
• ·Net cash generated from operations declined to £731m from £811m.
• ·Portfolio changes: +£7m sales, +£2m adj OP from eDynamic Learning acquisition and Copp Clark disposal.

13-03-2026

Emerald Holding, Inc. reported FY 2025 revenues of $463.4M, up 16.2% YoY driven by acquisitions, with Organic Revenues up a modest 1.1% to $397.0M and Adjusted EBITDA rising 25.0% to $127.1M; however, it posted a net loss of $30.7M versus prior-year income of $2.2M, and cash from operations declined 9.0% to $42.6M. Q4 2025 revenues grew 24.3% to $132.7M with Organic Revenues nearly flat at +0.3% ($105.0M), Adjusted EBITDA up 9.7% to $36.3M, but net loss of $30.2M versus $5.1M income prior, and Free Cash Flow down 43.6% excluding insurance. The company issued FY 2026 guidance of $490-495M revenue and $137.5-142.5M Adjusted EBITDA, repurchased $17.5M in shares, declared a $0.015/share dividend, and announced a strategic review following acquisition inquiries.

• ·Pro forma Organic Revenue growth including recent acquisitions: 4.8% FY 2025, 5.3% Q4 2025.
• ·SG&A expenses FY 2025 up 41.5% to $241.2M due to $58.3M acquisition-related items.
• ·$25M share repurchase authorization remaining as of Dec 31, 2025.
• ·Dividend payable April 2, 2026 to holders as of March 23, 2026.

13-03-2026

Perfect Corp. reported revenue growth of 14.9% YoY to $69.2M in 2025 from $60.2M in 2024, with gross profit up 14.0% to $53.5M and operating loss narrowing 45.0% to $1.7M amid reductions in G&A expenses. However, net income declined 7.5% YoY to $4.6M due to a 28.4% surge in R&D expenses to $15.4M, a $2.0M goodwill impairment, and falling interest income (-20.4% to $6.1M). Total assets expanded to $192.0M, supported by a $6.0M subsidiary acquisition, while cash from operations remained flat at $13.3M and cash balances dipped slightly to $126.0M.

• ·Total equity increased to $153.1M as of Dec 31 2025 from $147.0M in 2024.
• ·Share-based payment transactions: $1.4M in 2025, down from $2.8M in 2024.
• ·Earnings per share remained flat at $0.05 basic and diluted for Class A and B shares across 2023-2025.

13-03-2026

BRT Apartments Corp. reported total revenues of $97.0M for 2025, up 1.5% YoY from $95.6M, primarily driven by loan interest income surging 105.7% to $1.8M, while rental revenues grew modestly 0.5% to $95.3M. However, GAAP net loss attributable to common stockholders widened to $(11.9M) or $(0.63) per share from $(9.8M) or $(0.52), same-store NOI declined slightly to $49.9M from $50.1M, and total NOI was essentially flat at $51.2M. Adjusted Funds from Operations (AFFO) improved modestly to $27.4M ($1.45 per share) from $26.7M ($1.43), reflecting flat to low growth amid rising expenses.

• ·Owned portfolio: 21 properties with 5,420 units across 11 states + other; top contributor Tennessee (15% of revenue, 702 units).
• ·JV portfolio: 10 properties with 2,891 units; Texas (41% of JV revenue, 1,103 units) and South Carolina (38%) dominant.
• ·Long-term debt: Balloon principal payments total $720.3M, with $88.7M due <1 year and $384.4M >5 years.
• ·Purchase obligations: $30.4M through 5 years.

13-03-2026

Vaxart reported FY2025 revenue of $237K, up 727% YoY from $29K in FY2024, driven by government contracts surging 803% to $225K, leading to operating income of $18K and net income of $16K versus prior-year losses. However, operating expenses rose 131% to $219K, primarily due to R&D increasing 172% to $202K, while non-cash royalty revenue declined 50% and future royalties face risks from Inavir's compound patent expiration in 2024 enabling generic competition. Patent protection for Inavir in Japan extends to August 2036.

• ·Relenza last patent expired July 2019.
• ·Inavir laninamivir octanoate compound patent expired 2024, enabling generic competition and potential royalty decrease.
• ·Inavir last Japanese patent expires August 2036, after which royalties cease.
• ·Foreign withholding tax on royalty revenue: $96 (down 50% YoY).

13-03-2026

Red River Bancshares Inc (RRBI) reported robust 2025 financial results in its 10-K, with net income rising 25% YoY to $42.8M, total assets growing 6% to $3.35B, loans held for investment up 8% to $2.25B, and net interest margin FTE expanding 14% to 3.38% amid higher loan yields. ROA improved to 1.33% and ROE to 12.58%, with efficiency ratio declining to 55.84%. However, noninterest income fell 2% to $20.0M due to declines in mortgage loan income (-4%) and SBIC income (-96%), while NPAs to assets edged up to 0.11% and total risk-based capital ratio slipped slightly to 18.03%.

• ·Efficiency ratio improved to 55.84% in 2025 from 60.29% in 2024.
• ·ACL to loans HFI stable at 1.04% in 2025 vs 1.05% in 2024.
• ·Net charge-offs to average loans remained low at 0.03% in both 2025 and 2024.
• ·Tier I leverage capital ratio well above minimum at 12.21% as of Dec 31, 2025.

13-03-2026

SenesTech, Inc. reported FY2025 net revenues of $2.22M, up 20% YoY from $1.86M, driven by Evolve product sales surging to $1.81M (81% of total) from $1.23M (66%), while ContraPest revenues declined to $0.41M (19%) from $0.63M (34%). Gross profit improved 38% to $1.39M, but total operating expenses rose 9% to $7.89M amid higher SG&A costs, leading to a slightly narrower net loss of $6.38M (versus $6.18M in FY2024) and loss per share of $(1.95) versus $(8.86). Cash and equivalents strengthened to $7.58M from $1.31M, supported by $13.12M in financing activities.

• ·Weighted average shares outstanding increased to 3,275,983 in FY2025 from 697,974 in FY2024.
• ·Stockholders’ equity rose to $9.57M as of Dec 31, 2025 from $2.51M as of Dec 31, 2024.
• ·R&D expenses flat at approximately $1.70M YoY (decrease of $14k).

13-03-2026

Crane Company issued definitive additional proxy materials for its Annual Meeting of Stockholders on April 27, 2026, at 10:00 a.m. EDT at The Hyatt Regency Greenwich in Old Greenwich, CT. Shareholders are to vote on electing nine director nominees (Martin R. Benante, Sanjay Kapoor, Ronald C. Lindsay, Susan D. Lynch, Ellen McClain, Charles G. McClure, Jr., Max H. Mitchell, Jennifer M. Pollino, James L. L. Tullis), ratifying Deloitte & Touche LLP as independent auditors for 2026, and an advisory 'Say on Pay' vote for executive compensation, with the Board recommending FOR all proposals. Proxy materials are available online at www.envisionreports.com/CR, with paper copy requests due by April 13, 2026, and votes due by 8:00 a.m. EDT on meeting day.

• ·Voting for Crane Company Savings and Investment Plan shares has separate deadlines not specified here.
• ·Proxy materials requests via phone: 1-866-641-4276 or email to investorvote@computershare.com.

13-03-2026

Karman Holdings Inc. executed a Fourth Amendment to its Credit Agreement on March 9, 2026, adding $100M in incremental revolving credit commitments from new lenders, increasing total revolving commitments to $150M for working capital and general corporate purposes. The amendment removes prior limits on incremental revolving commitments and confirms no Events of Default post-effectiveness, with solvency certified. Conditions precedent including representations, warranties, legal opinions, and KYC compliance were satisfied.

• ·Original Credit Agreement dated April 1, 2025; prior amendments: First on May 27, 2025, Second on October 24, 2025, Third on February 2, 2026
• ·Legal opinions from Willkie Farr & Gallagher LLP (New York counsel) and Stoel Rives LLP (Washington counsel to Systima Technologies, Inc. and Five Axis Industries, Inc.)